
Join to view full profile
3577 W 13 Mile RdSte 103Royal Oak, MI 48073
Phone+1 248-288-4500
Fax+1 248-288-0450
Dr. Nadeau is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1999 - 2002
Case Western Reserve University School of MedicineClass of 1999
Certifications & Licensure
MI State Medical License 2005 - 2027
OH State Medical License 1999 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PegasusEMR, Software Solutions Group, Inc, 2012, 2014-2015
Clinical Trials
Publications & Presentations
PubMed
- Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patie...Yastira Ramdas, Trenton Reinicke, Carolyn A Schnurr, Laura Nadeau, Dana Zakalik
Frontiers in Oncology. 2025-01-01 - 4 citationsPhase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-09-01 - Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-08-01
Press Mentions
Phase 2 Study of Duvelisib in Previously Treated Patients with Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)December 12th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









